(Q37050998)

17 August 2017

1 reference

title

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer (English)

1 reference

17 August 2017

0 references

A M Krieg

1

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 January 2008

1 reference

17 August 2017

1 reference

17 August 2017

volume

27

1 reference

17 August 2017

issue

2

1 reference

17 August 2017

page(s)

161-167

1 reference

Pathogen recognition and innate immunity

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

Human lung cancer cells express functionally active Toll-like receptor 9

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

The adaptor molecule MyD88 activates PI-3 kinase signaling in CD4+ T cells and enables CpG oligodeoxynucleotide-mediated costimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

Toll-like receptors stimulate human neutrophil function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

Toll-like receptor control of the adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

Therapeutic potential of Toll-like receptor 9 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

Development of TLR9 agonists for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

Ligand-induced conformational changes allosterically activate Toll-like receptor 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

Maintenance of colonic homeostasis by distinctive apical TLR9 signalling in intestinal epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

CpG DNA-mediated immune response in pulmonary endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

CpG oligodeoxynucleotide enhances tumor response to radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

Microbial DNA induces a host defense reaction of human respiratory epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

Pros and Cons of Adjuvant Interferon in the Treatment of Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

Human monocytes infected with Yersinia pestis express cell surface TLR9 and differentiate into dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

FDG-PET for detection of recurrences from malignant primary bone tumors: comparison with conventional imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

Prognosis of Premenopausal Breast Cancer and Childbirth Prior to Diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

7 January 2021

Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

7 January 2021

Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

7 January 2021

Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

7 January 2021

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

7 January 2021

Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1210911

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1210911

1 reference

Dimensions Publication ID

17 August 2017

1045674326

0 references

1 reference